UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission file number: 001-40231
Universe Pharmaceuticals INC
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
On September 1, 2026, Universe Pharmaceuticals INC (the “Company”) filed a report on Form 6-K (the “Original 6-K”), announcing the annual general meeting of shareholders of the Company (the “Meeting”) and attaching thereto a notice and proxy statement for the Meeting and a form of proxy card.
This Amendment No. 1 on Form 6-K/A is being filed to include Annex A to the notice and proxy statement, which was inadvertently omitted from Exhibit 99.1 to the Original 6-K. Attached hereto as Exhibit 99.1 is the notice and proxy statement that will be sent to shareholders of the Company. No other changes have been made to the notice and proxy statement for the Meeting.
| 1 |
Exhibits
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Universe Pharmaceuticals INC. | ||
| Date: September 3, 2026 | By: | /s/ Gang Lai |
| Gang Lai | ||
| Chief Executive Officer | ||
| 3 |